Browse the search results

Page 3 of 7
    1. Microbiology and Infectious Disease

    A randomized feasibility trial comparing four antimalarial drug regimens to induce Plasmodium falciparum gametocytemia in the controlled human malaria infection model

    Isaie J Reuling et al.
    Controlled human malaria infection model allows the study of gametocyte biology and dynamics providing novel insights and tools in malaria transmission and elimination efforts.
    1. Epidemiology and Global Health

    Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development

    Camila Tenorio França et al.
    Antibody responses to individual and optimal combinations of P. vivax recombinant proteins in naturally-exposed populations help to identify correlates of protective immunity, and establish a clear path to testing a multicomponent P. vivax vaccine.
    1. Genetics and Genomics
    2. Microbiology and Infectious Disease

    Rapid and iterative genome editing in the malaria parasite Plasmodium knowlesi provides new tools for P. vivax research

    Franziska Mohring et al.
    Optimised genome editing in P. knowlesi enables transgenic expression of a lead P. vivax vaccine candidate, revealing roles in host cell tropisms and providing tools for scalable vaccine efficacy testing.
    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease

    Structural basis for inhibition of erythrocyte invasion by antibodies to Plasmodium falciparum protein CyRPA

    Lin Chen et al.
    The crystal structures of the key vaccine candidate CyRPA alone and in complex with antibody Fab fragment was solved and this will be important information for designing a vaccine.
    1. Cancer Biology
    2. Cell Biology

    PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors

    Kaixuan Shi et al.
    A functional ovarian-specific PAX8-centric regulon is susceptible to FDA-approved HDAC inhibitors, providing the rationale to target human cancers driven by lineage-survival oncogenes with epigenetic therapeutics perturbing the enhancer topology.
    1. Epidemiology and Global Health
    2. Microbiology and Infectious Disease

    Mapping the zoonotic niche of Ebola virus disease in Africa

    David M Pigott et al.
    Understanding where future Ebola virus outbreaks may start and the changing nature of the populations living in these places is of critical importance in helping to prepare for future outbreaks.
    1. Structural Biology and Molecular Biophysics

    Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug emetine

    Wilson Wong et al.
    The molecular mechanism behind how emetine inhibits the ribosome of the human malaria parasite, along with structural details of the complex formed, is revealed at high resolution using cryo-electron microscopy.
    1. Epidemiology and Global Health

    Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection

    Thomas S Churcher et al.
    Identifying and treating those groups of individuals that are most likely to transmit the malaria parasite to mosquitoes could help to control the spread of the disease.
    1. Microbiology and Infectious Disease

    A druggable secretory protein maturase of Toxoplasma essential for invasion and egress

    Sunil Kumar Dogga et al.
    An aspartyl protease is essential for the lytic cycle of Toxoplasma gondii and is involved in the maturation of proteins critical for invasion and egress, and it can be targeted selectively with an ethylamine scaffold based peptidomimetic inhibitor.
    1. Epidemiology and Global Health

    Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy

    Maia A Rabaa et al.
    In large vaccine trials conducted in dengue-endemic Asia and Latin America, the CYD-TDV tetravalent dengue vaccine shows limited variation in intra-serotype efficacy in the target population for vaccination (>9 years).